12 Warning Signs of MALT Lymphoma to Watch for

Could a slow-growing lymphoma hide behind symptoms that seem ordinary at first? MALT lymphoma, short for mucosa-associated lymphoid tissue lymphoma, is a type of non-Hodgkin lymphoma that usually develops in tissues lining organs rather than in lymph nodes. It is often considered an indolent, or slow-growing, cancer, but that does not mean it should be ignored.

MALT lymphoma is uncommon. It accounts for about 5% to 8% of non-Hodgkin lymphomas, and the stomach is the most common site. In many gastric cases, long-term infection with Helicobacter pylori, or H. pylori, plays an important role. This connection is one reason some early stomach MALT lymphomas may improve after antibiotic treatment that clears the infection.

The challenge is that MALT lymphoma can look different depending on where it appears. In the stomach, it may cause indigestion, stomach pain, nausea, loss of appetite, weight loss, or bleeding. In the eyes, lungs, salivary glands, thyroid, skin, or intestines, the warning signs may be entirely different. Some people have mild symptoms for months, while others discover it during tests for another health concern.

This article explains 12 warning signs of MALT lymphoma to watch for. These symptoms do not always mean cancer, and many are caused by more common conditions. Still, persistent swelling, unexplained weight loss, night sweats, unusual fatigue, ongoing stomach problems, or symptoms that keep returning deserve medical attention. Knowing the signs can help you seek care earlier, ask better questions, and understand when the body may be signaling something more serious.

What is MALT Lymphoma?

MALT Lymphoma is a slow-growing (indolent) type of non-Hodgkin lymphoma that arises from B-lymphocytes within the Mucosa-Associated Lymphoid Tissue (MALT), a diffuse system of lymphoid cells found along mucosal linings throughout the body. To understand this condition better, it is essential to break down its components and common locations.

This form of cancer is unique because it originates outside of the major lymphatic organs like lymph nodes, a characteristic that defines it as an extranodal lymphoma. Its development is strongly linked to chronic inflammation, often triggered by persistent infections or autoimmune diseases, which stimulate the immune system in a specific location over a prolonged period.

This chronic stimulation can lead to genetic changes in the local B-cells, causing them to multiply uncontrollably and form a lymphoma. Because of its indolent nature, MALT lymphoma often progresses very slowly over many years, and its symptoms can be subtle and easily mistaken for other, more benign conditions, making early recognition a significant challenge.

How is MALT Lymphoma Medically Defined?

Medically, MALT lymphoma is defined as an extranodal marginal zone B-cell lymphoma, a specific subtype of non-Hodgkin lymphoma characterized by the uncontrolled proliferation of B-lymphocytes that originate in the marginal zone of MALT. This classification highlights several key features of the disease.

“Extranodal” signifies that the cancer begins in tissues outside of the lymph nodes, which is a departure from many other types of lymphoma. The term “marginal zone” refers to a specific anatomical region within secondary lymphoid follicles where these particular B-cells reside. These cells are part of the body’s adaptive immune system and are typically involved in responding to antigens encountered at mucosal surfaces.

More specifically, the development of MALT lymphoma is a multi-step process. It begins with a chronic inflammatory stimulus, such as a persistent bacterial infection like Helicobacter pylori in the stomach. This long-term stimulation causes the recruitment and proliferation of B-cells and T-cells, leading to the formation of organized lymphoid tissue where it is not normally prominent.

Within this environment of chronic immune activity, B-cells are prone to acquiring genetic mutations. Specific chromosomal translocations, such as t(11;18)(q21;q21), are frequently observed in MALT lymphoma and are believed to be critical events in its transformation from a reactive process to a malignant one.

These genetic alterations lead to the activation of signaling pathways that promote cell survival and uncontrolled growth, independent of the initial inflammatory trigger. Its indolent or slow-growing nature means that the malignant cells divide at a much slower rate compared to aggressive lymphomas, often resulting in a prolonged clinical course where symptoms develop gradually over months or even years.

Where in the Body Does MALT Lymphoma Commonly Develop?

MALT lymphoma most commonly develops in the stomach, accounting for approximately 50-70% of all cases, but it can arise in virtually any organ containing mucosal tissue. This wide distribution means the clinical presentation can vary significantly depending on the site of origin.

When it occurs in the stomach, it is referred to as gastric MALT lymphoma and is overwhelmingly associated with chronic H. pylori infection. The persistent inflammation from this infection creates the ideal microenvironment for the lymphoma to develop. Patients with gastric MALT lymphoma often experience symptoms that mimic common gastrointestinal issues, such as gastritis or peptic ulcer disease.

Beyond the stomach, MALT lymphoma is classified as non-gastric MALT lymphoma and can affect a diverse range of sites. Salivary Glands is a frequent non-gastric site, particularly the parotid gland. It is strongly associated with Sjögren’s syndrome, an autoimmune disorder that causes chronic inflammation of the salivary and lacrimal glands.

Ocular Adnexa (Eyes) includes the conjunctiva, lacrimal gland, and orbit. Ocular adnexal MALT lymphoma often presents as a painless, salmon-pink patch on the eye’s surface or as persistent swelling and redness. It has been linked to infection with the bacterium Chlamydia psittaci.

Pulmonary MALT lymphoma is rare and often asymptomatic, frequently discovered incidentally on a chest X-ray or CT scan. When symptoms do occur, they are non-specific, such as a chronic cough or shortness of breath.

Cutaneous MALT lymphoma typically appears as single or multiple red to purplish papules, plaques, or nodules on the skin. In some regions, it has been associated with Borrelia burgdorferi, the bacterium that causes Lyme disease.

MALT lymphoma of the thyroid is almost always seen in patients with a history of Hashimoto’s thyroiditis, an autoimmune condition leading to chronic inflammation of the thyroid gland. While less common than in the stomach, intestinal MALT lymphoma can occur and may be linked to certain infections, such as Campylobacter jejuni.

12 Warning Signs of MALT Lymphoma

Persistent Indigestion or Heartburn

This is often one of the earliest and most common complaints. It feels like a burning sensation or discomfort in the upper abdomen, frequently occurring after meals. Unlike occasional heartburn, this symptom is chronic and may not respond well to over-the-counter antacids.

Upper Abdominal Pain or Discomfort

Patients may describe a dull, gnawing ache or a feeling of pressure in the upper stomach area. The pain can be constant or intermittent and is caused by the physical presence of the tumor irritating the stomach wall and surrounding nerves.

Nausea and Vomiting

As the lymphoma grows, it can interfere with the stomach’s ability to process and empty food, leading to persistent feelings of nausea. In some cases, this can progress to vomiting, particularly if the tumor causes a partial obstruction.

Loss of Appetite

The chronic discomfort, pain, and nausea associated with gastric MALT lymphoma can naturally lead to a significant decrease in appetite. Individuals may find they no longer enjoy food or have any desire to eat.

Feeling Full After Eating a Small Amount (Early Satiety)

This occurs because the infiltrated and thickened stomach wall cannot stretch properly to accommodate a normal-sized meal. A person may feel uncomfortably full after consuming only a small portion of food, which can contribute to unintentional weight loss.

Lungs (Pulmonary MALT Lymphoma)

This form is often discovered incidentally, but when symptomatic, it can cause respiratory issues. A persistent, dry cough or shortness of breath (dyspnea), especially during physical activity, may develop as the tumor tissue infiltrates the lung’s airways or parenchyma. Less commonly, patients may experience chest pain or even cough up small amounts of blood (hemoptysis).

Eyes (Ocular Adnexal MALT Lymphoma)

This typically affects the conjunctiva (the clear membrane covering the white of the eye) or the lacrimal glands. The most classic sign is a painless, raised, salmon-pink patch on the surface of the eye. Other symptoms include persistent redness, irritation, blurred vision, excessive tearing, or a visible lump or swelling of the eyelid. It is often mistaken for chronic conjunctivitis or “pink eye.”

Skin (Cutaneous MALT Lymphoma)

This type presents with various skin lesions. Patients may notice single or multiple reddish to purplish rashes, patches, plaques, or nodules that develop slowly over time. These lesions are typically painless but can sometimes be itchy. They can appear anywhere on the body but are most common on the trunk and arms.

Salivary Glands

MALT lymphoma in the salivary glands, most often the parotid gland located in the cheek, typically manifests as a painless, firm swelling or a noticeable lump in the jaw area. This can sometimes be accompanied by symptoms of dry mouth (xerostomia) or dry eyes, particularly if it is associated with the autoimmune condition Sjögren’s syndrome.

Unexplained Weight Loss

This is defined as the unintentional loss of more than 10% of one’s body weight over a period of six months. This weight loss is not due to dieting or increased exercise but occurs because the cancer cells consume a significant amount of the body’s energy and may release substances that alter metabolism and suppress appetite.

Drenching Night Sweats

These are not just mild sweating; they are severe, drenching sweats that soak through pajamas and bedding, often requiring a change of clothes or sheets during the night. The exact mechanism is not fully understood but is thought to be related to cytokines and other chemicals released by the lymphoma cells that affect the body’s temperature regulation center in the brain.

Unexplained Fever

This refers to a persistent or recurrent fever of over 100.4°F (38°C) that occurs without any evidence of an underlying infection. The fever may come and go, often spiking in the evenings. Like night sweats, these fevers are believed to be caused by pyrogens (fever-inducing substances) released by the cancer cells as part of a systemic inflammatory response. The presence of any of these B symptoms warrants immediate medical attention as it can influence the prognosis and urgency of treatment.

Causes and Risk Factors for MALT Lymphoma

The primary cause of MALT lymphoma is chronic inflammation, which is most often triggered by persistent infections or underlying autoimmune diseases. This long-term stimulation of the immune system at a specific mucosal site is the central driver of the disease.

Unlike many cancers that are linked to inherited genetic syndromes, MALT lymphoma is predominantly an acquired condition resulting from an extended battle between the body’s immune system and a chronic irritant. The constant immune response leads to an accumulation of lymphoid tissue (MALT) in places where it is not normally found in large quantities, such as the stomach lining.

Within this environment of persistent cell turnover and activation, the B-lymphocytes are at a higher risk of undergoing genetic mutations that lead to their transformation into cancerous cells. This process explains why MALT lymphoma can develop in so many different parts of the body, wherever there is mucosa and a potential for chronic inflammation.

The Connection Between H. pylori Infection and MALT Lymphoma

The connection between Helicobacter pylori (H. pylori) infection and gastric MALT lymphoma is one of the clearest and most well-established causal links in oncology. H. pylori is a bacterium that colonizes the stomach lining, and chronic infection is a leading cause of gastritis, peptic ulcers, and stomach cancer. In the context of MALT lymphoma, the infection acts as a powerful and persistent antigenic stimulus.

The body’s immune system mounts a continuous attack against the bacterium, leading to the recruitment of a large number of immune cells, including T-cells and B-cells, to the stomach lining. This results in the formation of acquired MALT in the stomach.

More specifically, the process unfolds in a predictable sequence. The T-cells responding to H. pylori provide help to local B-cells, causing them to proliferate. Over time, some of these B-cells can acquire specific genetic mutations, such as the chromosomal translocation t(11;18). This mutation creates a fusion protein called API2-MALT1, which activates a cellular pathway known as NF-κB, giving the B-cells a survival advantage and allowing them to grow uncontrollably, independent of the initial T-cell help.

This transforms a reactive immune process into a malignant lymphoma. The remarkable aspect of this connection is its therapeutic implication: in over 75% of patients with early-stage, localized gastric MALT lymphoma, treating and eradicating the underlying H. pylori infection with a course of antibiotics is enough to cause the lymphoma to regress and, in many cases, completely disappear without the need for chemotherapy or radiation.

Other Infections or Autoimmune Diseases Considered Risk Factors

Beyond H. pylori, a range of other chronic infections and autoimmune diseases are recognized as significant risk factors for developing non-gastric MALT lymphoma. The underlying principle remains the same: chronic antigenic stimulation and inflammation in a specific organ drive the development of the lymphoma. Each site of non-gastric MALT lymphoma is often associated with a particular inflammatory trigger, highlighting the localized nature of this disease.

Sjögren’s Syndrome is an autoimmune disease where the immune system mistakenly attacks the glands that produce tears and saliva, leading to chronic inflammation. Patients with Sjögren’s syndrome have a significantly increased risk—up to 44 times higher than the general population—of developing MALT lymphoma in their salivary glands.

Hashimoto’s Thyroiditis involves chronic inflammation of the thyroid gland, which is gradually destroyed by the immune system. It is the most common cause of hypothyroidism in developed countries and is strongly linked to the development of primary thyroid MALT lymphoma.

Chlamydia psittaci, typically associated with birds, has been identified as a risk factor for ocular adnexal MALT lymphoma (lymphoma of the eye). Similar to H. pylori in the stomach, antibiotic treatment targeting C. psittaci can lead to lymphoma regression in some patients.

Borrelia burgdorferi responsible for Lyme disease has been implicated in the development of cutaneous (skin) MALT lymphoma, particularly in endemic regions of Europe. Chronic infection in the skin is thought to be the inflammatory trigger.

Campylobacter jejuni is a common cause of food poisoning and gastroenteritis. In rare cases, chronic infection has been linked to a specific type of intestinal MALT lymphoma known as immunoproliferative small intestinal disease (IPSID).

MALT Lymphoma Diagnosis

MALT lymphoma is diagnosed through a comprehensive process that includes a physical examination, review of medical history, blood tests, imaging scans, and, most critically, a tissue biopsy of the affected area for pathological analysis. The diagnostic journey typically begins when a patient presents with persistent symptoms, such as the warning signs discussed earlier.

An initial evaluation by a healthcare provider will involve exploring these symptoms and assessing for potential risk factors like a history of H. pylori infection or an autoimmune disease. Because the symptoms are often non-specific, the diagnostic process is methodical, aiming to rule out more common conditions first.

Imaging studies like CT scans or ultrasounds may be used to visualize the affected organ and determine the extent of the disease, while blood tests provide information about the patient’s overall health and can detect abnormalities like anemia. However, these tests alone cannot confirm MALT lymphoma; the definitive diagnosis hinges on obtaining a tissue sample.

Is a Biopsy Always Required For a Definitive Diagnosis?

A biopsy is absolutely essential and is the gold standard for a definitive diagnosis of MALT lymphoma. While imaging and blood tests can suggest the presence of a lymphoma, they cannot confirm it.

Only by examining a sample of the suspicious tissue under a microscope can a pathologist identify the characteristic features of the cancer cells and distinguish MALT lymphoma from other conditions, such as infections, benign inflammatory processes, or other types of cancer. The procedure for obtaining the biopsy depends on the location of the suspected lymphoma.

For gastric MALT lymphoma, the most common type, a biopsy is typically performed during an upper endoscopy (also known as an esophagogastroduodenoscopy or EGD). During this procedure, a doctor inserts a thin, flexible tube with a light and camera through the patient’s mouth to visualize the lining of the esophagus, stomach, and duodenum. Small forceps are passed through the endoscope to take multiple tissue samples from any abnormal-looking areas.

Once the tissue is obtained, it is sent to a pathology lab for detailed analysis. The pathologist examines the cellular architecture and performs specialized tests like immunohistochemistry and flow cytometry. Immunohistochemistry uses antibodies to detect specific proteins (or markers) on the surface of the cells.

For MALT lymphoma, the cells will typically be positive for B-cell markers like CD20 and CD79a, and negative for other markers like CD5, CD10, and Cyclin D1, which helps differentiate it from other B-cell lymphomas. Genetic tests may also be performed to look for characteristic chromosomal translocations, such as t(11;18), which can provide further diagnostic confirmation and prognostic information.

Imaging and Blood Tests In the Diagnostic Process

Imaging and blood tests are crucial supportive tools in the diagnostic process, primarily used to assess the extent (stage) of the disease and evaluate the patient’s overall health. While the biopsy confirms the diagnosis, these tests provide a complete picture of the lymphoma’s impact on the body, which is vital for planning treatment.

For suspected gastric MALT lymphoma, an upper endoscopy is the primary diagnostic tool for visualization and biopsy. An EUS may be performed at the same time. This technique uses an ultrasound probe on the tip of the endoscope to create detailed images of the stomach wall and nearby lymph nodes, helping to determine how deeply the lymphoma has invaded.

CT scans of the chest, abdomen, and pelvis are standard for staging MALT lymphoma. They are used to look for evidence of the lymphoma in other parts of the body, such as other organs, distant MALT sites, or enlarged lymph nodes. This helps determine if the disease is localized (Stage I/II) or has spread (Stage III/IV).

Ultrasound is particularly useful for evaluating non-gastric sites that are close to the skin’s surface, such as the salivary glands, thyroid, or superficial lymph nodes.

Additionally, blood tests include a series of blood tests are routinely performed. Complete Blood Count (CBC) measures levels of red blood cells, white blood cells, and platelets. Anemia (low red blood cells) can occur due to chronic bleeding from a gastric tumor.

Comprehensive Metabolic Panel (CMP) assesses kidney and liver function, which is important to check before starting any treatment. Lactate Dehydrogenase (LDH) is an enzyme that can be elevated in patients with lymphoma, and high levels may correlate with a larger tumor burden.

Depending on the location, specific tests are done to identify underlying infections, such as a urea breath test, stool antigen test, or blood test for H. pylori.

Broader Medical Considerations for MALT Lymphoma

Beyond recognizing its warning signs, understanding the broader medical considerations for MALT lymphoma involves grasping its staging, types, prognosis, and unique treatment pathways, which are critical for effective management and long-term health outcomes.

Furthermore, these factors help differentiate MALT lymphoma from other, more aggressive forms of cancer, providing crucial context for patients and their families as they navigate the diagnosis and treatment process.

This deeper knowledge encompasses how oncologists classify the disease’s spread, the significant differences between its common locations, its generally favorable outlook compared to other lymphomas, and its remarkable sensitivity to non-chemotherapeutic treatments in specific cases. Each of these elements plays a vital role in creating a comprehensive and personalized care plan tailored to the individual’s specific circumstances.

How is MALT Lymphoma Staged?

The staging of MALT lymphoma, like most lymphomas, is primarily determined using the Ann Arbor staging system, which classifies the extent of the cancer’s spread throughout the body. Because MALT lymphoma is an extranodal lymphoma, meaning it originates in tissues outside of the lymph nodes, a modifier “E” is often added to the stage (e.g., Stage IE).

For MALT lymphoma, which commonly begins in a single organ like the stomach, the staging is crucial for determining the treatment approach and prognosis. Stage IE is the most common presentation, indicating the lymphoma is confined to a single extranodal site.

This localized nature at diagnosis is a key reason for its generally positive outlook. As the disease progresses, it can involve nearby lymph nodes or spread to more distant sites, elevating its stage and often necessitating more systemic therapies beyond localized treatments like antibiotics or radiation.

Stage I (IE): The lymphoma is confined to a single extranodal site, such as the stomach, salivary gland, or a patch of skin. This is the earliest and most frequently diagnosed stage for MALT lymphoma.

Stage II (IIE): The lymphoma involves an extranodal site and its nearby lymph nodes on the same side of the diaphragm. For example, a gastric MALT lymphoma that has also spread to abdominal lymph nodes would be considered Stage IIE.

Stage III: The lymphoma involves lymph node regions on both sides of the diaphragm, or it involves an extranodal site and lymph nodes on the opposite side of the diaphragm. This stage indicates more widespread disease.

Stage IV: The lymphoma has disseminated widely, involving one or more extranodal organs (like the liver or bone marrow) in a non-contiguous fashion, with or without associated lymph node involvement.

The Difference Between Gastric and Non-gastric MALT Lymphoma

The fundamental difference between gastric and non-gastric MALT lymphoma lies in their location, primary underlying cause, and subsequent treatment strategies. Gastric MALT lymphoma develops in the mucosal lining of the stomach and accounts for the majority of MALT lymphoma cases. Its development is strongly and uniquely linked to chronic infection with the bacterium Helicobacter pylori (H. pylori). This bacterium triggers chronic inflammation in the stomach lining, which, over time, can cause B-cells to undergo cancerous transformation.

In contrast, non-gastric MALT lymphoma arises in tissues outside of the stomach. Common sites include the salivary glands, thyroid, lungs, skin, and the tissues surrounding the eye (ocular adnexa). The drivers for non-gastric MALT lymphoma are more varied and often associated with other chronic inflammatory or autoimmune conditions rather than a single bacterial infection.

The Prognosis for MALT Lymphoma Compared to Other Lymphomas

The prognosis for MALT lymphoma is generally very favorable and significantly better than that of many other types of non-Hodgkin lymphoma (NHL). This positive outlook is primarily due to its nature as an indolent lymphoma, meaning it grows very slowly over many years and often remains localized to its site of origin for a long period.

In many cases, especially when diagnosed at an early stage, it can be managed effectively with minimal or non-invasive treatments, leading to high rates of long-term survival. The 5-year overall survival rate for patients with localized MALT lymphoma often exceeds 90%.

This contrasts sharply with aggressive lymphomas, such as Diffuse Large B-cell Lymphoma (DLBCL), which grow rapidly, cause severe symptoms quickly, and require immediate and intensive chemotherapy to achieve a cure. While DLBCL is potentially curable, its aggressive nature poses a much greater immediate threat to the patient.

Early-stage gastric MALT lymphoma associated with H. pylori shows a remarkable response to antibiotic therapy, with remission rates between 70% and 80%. For cases that do not respond or are non-gastric, localized radiation therapy also offers excellent long-term control with minimal side effects. Even in the rare event that it transforms into a more aggressive lymphoma, initial management as an indolent disease contributes to a better overall journey for the patient.

FAQs

1. How quickly do MALT lymphoma symptoms develop?

MALT lymphoma symptoms often develop slowly over months or even years. Some people notice mild, vague symptoms at first, such as indigestion, fatigue, swelling, or discomfort in the affected area. Because it is usually slow-growing, it may be found during tests for another condition.

2. What does stage 1 lymphoma feel like?

Stage 1 lymphoma may cause few or no symptoms. When symptoms appear, they often depend on where the lymphoma starts. A person may notice a lump, swelling, stomach discomfort, tiredness, or unexplained changes in appetite or weight. Some early-stage cases are discovered before obvious symptoms develop.

3. What is the 10-year survival rate for MALT lymphoma?

MALT lymphoma generally has a favorable outlook, especially when found early. Many studies report 10-year survival rates around 80% to 90%, though this varies by age, stage, site of disease, overall health, and whether the lymphoma transforms into a more aggressive type.

4. Which bacteria causes MALT lymphoma?

Helicobacter pylori, often called H. pylori, is strongly linked to gastric MALT lymphoma. Long-term infection can cause chronic inflammation in the stomach lining, which may contribute to lymphoma development in some people.

5. Where does MALT lymphoma start?

MALT lymphoma starts in mucosa-associated lymphoid tissue, which is immune tissue found in areas such as the stomach, salivary glands, thyroid, lungs, eyes, skin, and intestines. The stomach is the most common location.

6. What is the new name for MALT lymphoma?

MALT lymphoma is commonly classified as extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Many people still use the shorter name, MALT lymphoma, because it is easier to recognize.

7. Can MALT lymphoma turn into a different lymphoma?

Yes, in some cases MALT lymphoma can transform into a faster-growing lymphoma, most often diffuse large B-cell lymphoma. This is uncommon, but it is one reason regular follow-up is important, even when the disease seems slow-growing.

Conclusion

MALT lymphoma is often slow-growing, but its warning signs should still be taken seriously. Ongoing stomach discomfort, unexplained weight loss, night sweats, persistent fatigue, swelling, bleeding, or symptoms in the eyes, lungs, skin, thyroid, or salivary glands may need medical evaluation.

Because MALT lymphoma can begin in different parts of the body, symptoms are not the same for everyone. Some people have clear signs, while others learn about it after imaging, endoscopy, biopsy, or blood tests done for another reason. Early diagnosis can help doctors choose the right treatment, which may include antibiotics, radiation, immunotherapy, chemotherapy, or careful monitoring.

The most important message is simple: persistent symptoms deserve attention. When unusual changes do not improve or keep returning, getting checked can bring clarity, reassurance, and earlier treatment when needed.

References

• Blood Cancer UK – About MALT lymphoma
• Cleveland Clinic – MALT Lymphoma
• Lymphoma Action – MALT lymphoma
• Mayo Foundation for Medical Education and Research – Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)
• Blood Cancer UK – Symptoms and diagnosis of MALT lymphoma
• National Library of Medicine – Pre-malignant signs of gastric MALT lymphoma
• The University of Texas MD Anderson Cancer Center – What is MALT lymphoma? 6 things to know
• ABOUT BLOOD CANCERS – MALT Lymphoma
• Cancer Research UK – MALT lymphoma
• Autops Case Rep – Pre-malignant signs of gastric MALT lymphoma